A new study explains the genetic grounds of a rare and aggressive form of ovarian cancer – and provides a possible passage for new treatment.

High-grade serous carcinoma, the most common type of ovarian cancer, usually begins in the fallopian tubes before spreading to the ovaries and other pelvic organs. Cancer is usually discovered in an advanced stage and becomes resistant to current chemotherapy. Its inherent genetics are complex with many genetic changes and instability. One of the involved genes is CDK12.

In this new study, published in Action of National Science AcademyResearchers at the University of Michigan reported on a new mouse model of Michigan Rosel Cancer Center, which shows CDK 12 that the mouse is equivalent to a tumor mitigation to run the high-grade serous carcinoma that arises in the mouse ovid. CDK12 and a related gene, a promising derogatory targeting CDK13, can destroy these tumors.

This is the first performance in a mouse model CDK12 plays the role of a tumor mitigation in this type of cancer. When we deactivate CDK12, the tumor grows very fast and mice die soon, showing that it is a more aggressive form of the disease. ,

Arul M. Chinnayan, MD, PhD, Co-C-C-C-C-Cerend

The mouse model used in this work was important for searching. This Kathleen R. Cho was based on a genetic model made earlier by MD, in which three genes known to suppress the development of high-grade serous carcinoma were removed in the mouse ovlect. Here, CDK12 was added to a quadruple inactivity of the gene.

Co-General Study Writer Cho, Peter A. of Pathology. Ward professor, co-director of Rogology, and co-director of Michigan Medicine, and co-director of Michigan Medicine, and co-director of Michigan Medicine, and co-director of Michigan Medicine, and for Mikigan Medicine, and for Mikigan Medicine, a procedure, a procedure, a process that is a process, is very important to show model systems.

“These characteristics include not only the microscope cells of the original and appearance, but also the time of tumor development, built -in genetics, acquired genetic changes and gene expression profiles, tumors microenequesment (including immune cell components) and other aspects of biological behavior,” he said.

The result here enabled researchers to see that in addition to promoting the development of aggressive tumors, neutralizing the CDK12 led to an immune cell response, immune recruitment. T cells For the tumor. In addition, the researchers identified a fellow gene, CDK13, which is a target for a derogatory or inhibitory of CDK12. A CDK12/13 degree with immune checkpoint inhibitors in the mouse model reduced the growth of the tumor, suggesting a combination therapy, may be effective in this sate of ovarian cancer.

“While there have been some improvements in the management of a high-grade serous carcinoma, once patients become resistant to first-rich chemotherapy, selection of other chemotheraputic agents is largely estimated. New remedies are required, because women are quite poor in the overall survival of women with this cancer type,” Cho said.

Chinnayan’s team first reported on similar findings in prostate cancer, which performs CDK12 as a major driver of aggressive disease. CDK12 is known for playing a role in about 7% of metastatic prostate cancer and about 3% tubo-Assemrian high-grade serous cancer. It has not been shown to be inactive in other cancer types.

Chinnayian said, “Types of treatment that can be tried in ovarian cancer are different from prostate cancer. Here, we bring two diseases together and show that CDK12/13 inhibitors or degraders should be considered in both these cancer types.”

Many CDK12/13 are in inhibitory development, in which the UM team has developed. Researchers have planned to further develop CDK12/13 degrees, with the target of carrying it to a clinical test.

Note for patients: This task is pre -pregnant and requires more research. A CDK12/13 degrader is currently not available in clinical trials. For information about questions about current clinical trials or questions about the treatment of ovarian cancer, call or travel to Michigan Medicine Cancer North line 800-865-1125 www.rogelcanceercector.org/clinical-trials,